Nerandomilast

Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis.^[1] It is a phosphodiesterase 4 (PDE4) inhibitor.^[1] It is taken by mouth.^[1]

Nerandomilast

Clinical data
Trade names	Jascayd
Other names	BI-1015550
AHFS/Drugs.com	Jascayd
License data	US DailyMed: Nerandomilast
Drug class	Phosphodiesterase-4 inhibitor
ATC code	None
Legal status
Legal status	US: ℞-only[1]
Identifiers
CAS Number	1423719-30-5
PubChem CID	166177189
DrugBank	DB18237
ChemSpider	129160248
UNII	I5DGT51IB8
KEGG	D12975
Chemical and physical data
Formula	C20H25ClN6O2S
Molar mass	448.97 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC(C1)(CO)NC2=NC(=NC3=C2[S@](=O)CC3)N4CCC(CC4)C5=NC=C(C=N5)Cl
InChI InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)/t30-/m1/s1 Key:UHYCLWAANUGUMN-SSEXGKCCSA-N

Nerandomilast was approved for medical use in the United States in October 2025.^[1]

Medical uses

Nerandomilast is indicated for the treatment of idiopathic pulmonary fibrosis in adults.^[1]

Society and culture

Legal status

Nerandomilast was approved for medical use in the United States in October 2025.^[1][2]

Names

Nerandomilast is the international nonproprietary name.^[3]

Nerandomilast is sold under the brand name Jascayd.^[1]